Enriched Injectable Emulsion for Stable Omega-3 Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current parenteral lipid emulsions face challenges with the water-insolubility of long-chain and medium-chain fatty acids, leading to stability and toxicity concerns, and contain undesirable fatty acids that can interfere with therapeutic efficacy, particularly in critically ill patients.
Innovation Solution
A composition of triglycerides esterified with three identical or different fatty acids, such as caprylic acid, capric acid, alpha-linolenic acid, and eicosapentaenoic acid, with a concentration greater than 60% for parenteral administration, designed to provide a highly purified and concentrated source of omega-3, omega-6, and omega-9 fatty acids, enhancing therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If triglyceride-based oil-in-water emulsion is used to deliver long-chain fatty acids intravenously, then water-insolubility is overcome and safe administration is achieved, but physical stability is compromised due to interfacial tension between oil and water phases
Solution Approach 1:
The patent uses egg phospholipids as an emulsifying agent that acts as an intermediary between the oil phase (triglycerides containing fatty acids) and water phase. The phospholipids have amphipathic properties with hydrophilic heads and hydrophobic tails, allowing them to position at the interface and reduce interfacial tension, thereby stabilizing the emulsion while maintaining intravenous administrability
Solution Approach 2:
The invention creates a composite emulsion system combining multiple components: triglycerides (oil phase), water (aqueous phase), and egg phospholipids (emulsifier). This composite structure leverages the complementary properties of each component to achieve both intravenous compatibility and physical stability that neither phase could provide alone
2Adaptability or versatility
If conventional lipid emulsions containing multiple fatty acids are used, then comprehensive nutritional support is provided, but undesirable fatty acids interfere with therapeutic efficacy in critically ill patients
Solution Approach 1:
The patent extracts and isolates specific desirable fatty acids (omega-3, omega-6, and omega-9 fatty acids with 18-22 carbon chains) from the complex mixture of fatty acids found in conventional lipid emulsions. By formulating the emulsion with only these selected fatty acids bound to triglycerides, the invention eliminates undesirable fatty acids that could interfere with therapeutic efficacy while maintaining nutritional support capabilities
3Ease of manufacture
If medium-chain fatty acids are used in injectable emulsion, then some are available as ethyl esters, but stability and toxicity concerns arise when prepared as sterile lipid injectable emulsion dosage forms
Solution Approach 1:
The patent changes the molecular form of medium-chain fatty acids from ethyl esters to triglyceride form. This parameter change (molecular structure modification) transforms the chemical properties, improving stability in sterile injectable emulsion dosage forms while maintaining the desired fatty acid delivery function and reducing toxicity concerns associated with ethyl ester formulations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition ensures precise dosing and reduced toxicity, improving therapeutic outcomes by minimizing undesirable fatty acids and enhancing the bioavailability and therapeutic effects of omega-3 and omega-6 fatty acids in critically ill patients.
Implementation Method 1
triglyceride-based, oil-in-water emulsion delivery system
Implementation Method 2
lowering the interfacial tension between oil and water by using an amphoteric emulsifying agent, such as egg phospholipids
Data Source
AI summary
A composition including a triglyceride containing glycerol which is esterified with three fatty acids, wherein the three fatty acids include at least one fatty acid selected from caprylic acid, capric acid, α-linolenic acid, linoleic acid, oleic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid. The total amount of caprylic acid, capric acid, a-linolenic acid, linoleic acid, oleic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid is greater than 60%, based on the total weight of the fatty acids in a base or starting emulsion. The various physical mixtures of triglycerides containing the primary therapeutic fatty acid can be blended to form pre-defined amounts for the treatment of various acute pathological conditions.